About us
Simris is a biotechnology company committed to transforming cancer treatment through its proprietary pipeline of next-generation ADC payloads. These payloads are born from world-class cyanobacterial science, proprietary conjugation methods, and collaborations with leading research institutions.
We are currently optimising novel Microcystin toxin variants for use in advanced ADCs, targeting both haematologic and solid tumours.
Our research team leverages close to 20 years of cyanobacteria expertise and our exclusive strain library to efficiently develop and scale novel payloads. This unique platform gives Simris a significant competitive edge in the emerging ADC landscape.
We operate a collaboration-first strategy, building value through partnerships with biopharma companies committed to delivering the next leap in targeted cancer therapies.
Simris Group is headquartered in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market (SIMRIS, ISIN: SE0008091664).
Name: Daniel Kubitza
Title: Interim Chief Executive Officer since November 2025
Born: 1968
Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry.
Founder and Partner of ELSA Advisory,
Member of the strategic committee of ADDEV Materials Group
Member of Treasury committee of Handicap International in France
Mandate with WHO/IRAC on diabetes project
Holdings: 0 B-shares
Name: Christoffer Tell
Title: Chief Financial Officer since Feb 2021
Born: 1987
Christoffer has over 10 years of experience in leading roles across different industry sectors. Previous to Simris Christoffer held the position of CFO för Global Gaming and CFO för Examec Group. Today he works as an independent consultant and auditor.
Christoffer Tell AB - Board member.
CORMKA AB – Chairman.
Mainstream Media Scandinavia AB - Chairman, CEO.
Simrishamns Låsservice AB - Board deputy.
Newbury Pharmaceuticals AB - CFO.
Holdings: 1 200 000 B-shares, 0 warrants.